Trial reportThe Journal of urology2021
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with
Trial report in The Journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 205 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-center, Open-label, Single Arm Phase III Clinical Trial for the Diagnostic Efficacy Assessment and Safety Evaluation by [18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer
A Two Center Phase 2 Trial of 61Cu-noDAGa-PSMA I&T (61Cu-NU101) for Patients With Prostate Cancer
Who cites it
205 citing papers in PubMed, 5 syntheses or guidelines pooled it, 354 citations in OpenAlex.
- Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use ofClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Guideline
- The Homunculus of unspecific bone uptakes associated with PSMA-targeted tracers: a systematic review-based definition.European journal of nuclear medicine and molecular imaging · 2024Pooled it
- Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy.World journal of urology · 2024Pooled it
- Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Pooled it
- PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0.European journal of nuclear medicine and molecular imaging · 2023Guideline
- Exploratory FDG PET/CT Imaging in mCRPC Patients Treated with Sipuleucel-T ± IL-7: A Phase II Trial Subanalysis.International journal of molecular sciences · 2026Trial
- Lymph node dissection based on 18F-PSMA PET/CT during radical prostatectomy for intermediate and high risk prostate cancer: interim results of a prospective, randomized study.Prostate cancer and prostatic diseases · 2026Trial
- The German Cancer Consortium (DKTK) multi-center prospective phase 1/2European journal of nuclear medicine and molecular imaging · 2026Trial
- Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115).International journal of radiation oncology, biology, physics · 2025Trial
- Imaging Efficacy of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Trial
- Impact of Concomitant Hormone Therapy on the Diagnostic Performance ofThe Prostate · 2025Trial
- Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial.The Journal of urology · 2024Trial
- AnCurrent radiopharmaceuticals · 2024Trial
- [European journal of nuclear medicine and molecular imaging · 2023Trial
- Trial
- High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged withMolecular imaging · 2022Trial
- Pelvic lymph node dissection in prostate cancer: current evidence, controversies, and future directions.Annals of medicine · 2026Review
- Early Identification and Management of Biochemical Recurrence Following Radical Prostatectomy.Annals of surgical oncology · 2026Review
- Management of De Novo miN1 Prostate Cancer in the PSMA-PET Era.The Prostate · 2026Review
- Article
145 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
17 authors at 13 institutions in 2 countries.
Funding
Abstract
purposeProstate specific membrane antigen-targeted positron emission tomography/computerized tomography has the potential to improve the detection and localization of prostate cancer. OSPREY was a prospective trial designed to determine the diagnostic performance of MATERIALS AND
methodsTwo patient populations underwent
resultsA total of 385 patients were enrolled. In cohort A (252 evaluable patients),
conclusionsThe primary end point for specificity was met while the primary end point for sensitivity was not. The high positive predictive value observed in both cohorts indicates that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.